دورية أكاديمية
Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
| العنوان: | Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer |
|---|---|
| المؤلفون: | Formisano, Luigi, Lu, Yao, Servetto, Alberto, Hanker, Ariella B., Jansen, Valerie M., Bauer, Joshua A., Sudhan, Dhivya R., Guerrero-Zotano, Angel L., Croessmann, Sarah, Guo, Yan, Gonzalez, Paula, Lee, Kyung-min, Nixon, Melissa J., Schwarz, Luis J., Sanders, Melinda E., Dugger, Teresa C., Rocha Cruz, Marcelo, Behdad, Amir, Cristofanilli, Massimo, Bardia, Aditya, O'Shaughnessy, Joyce, Nagy, Rebecca J., Lanman, Richard B., Solovieff, Nadia, He, Wei, Miller, Michelle, Su, Fei, Shyr, Yu, Mayer, Ingrid A., Balko, Justin M., Arteaga, Carlos L. |
| سنة النشر: | 2019 |
| المجموعة: | Dryad Digital Repository (Duke University) |
| مصطلحات موضوعية: | Breast Cancer |
| جغرافية الموضوع: | United States of America (USA) |
| الوصف: | Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Addition of the FGFR TKI erdafitinib to palbociclib/fulvestrant induced complete responses of FGFR1-amplified/ER+ patient-derived-xenografts. Next generation sequencing of circulating tumor DNA (ctDNA) in 34 patients after progression on CDK4/6 inhibitors identified FGFR1/2 amplification or activating mutations in 14/34 (41%) post-progression specimens. Finally, ctDNA from patients enrolled in MONALEESA-2, the registration trial of ribociclib, showed that patients with FGFR1 amplification exhibited a shorter progression-free survival compared to patients with wild type FGFR1. Thus, we propose breast cancers with FGFR pathway alterations should be considered for trials using combinations of ER, CDK4/6 and FGFR antagonists. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee K, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O’Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL (2019) Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications 10(1): 1373.; http://hdl.handle.net/10255/dryad.200284Test |
| DOI: | 10.5061/dryad.20j465p |
| الإتاحة: | https://doi.org/10.5061/dryad.20j465pTest https://doi.org/10.5061/dryad.20j465p/1Test https://doi.org/10.5061/dryad.20j465p/3Test https://doi.org/10.5061/dryad.20j465p/2Test https://doi.org/10.5061/dryad.20j465p/4Test https://doi.org/10.5061/dryad.20j465p/5Test https://doi.org/10.5061/dryad.20j465p/6Test https://doi.org/10.1038/s41467-019-09068-2Test http://hdl.handle.net/10255/dryad.200284Test |
| رقم الانضمام: | edsbas.C0DD2DE8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.5061/dryad.20j465p |
|---|